Kunwar Shailubhai, chief scientific officer of OKYO Pharma Plc (), discusses with Proactive's Andrew Scott the new direction and investment strategy for the business following its name change earlier this year.
He says they've found two 'exciting' new technologies focused on dry eye and pain management.
"Both are worldwide epidemics ... we think there's a lot of opportunity'', he says.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE